| Matthew Garrett Field, MD, PHD, MSPH | |
|
9801 Dupont Ave S Ste 200, Bloomington, MN 55431-3200 | |
| (952) 888-5800 | |
| (952) 567-6156 |
| Full Name | Matthew Garrett Field |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Location | 9801 Dupont Ave S Ste 200, Bloomington, Minnesota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962060624 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | R-11586 (Iowa) | Secondary |
| 207W00000X | Ophthalmology | R-11586 (Iowa) | Secondary |
| 207W00000X | Ophthalmology | 73253 (Minnesota) | Primary |
| Entity Name | Group Health Plan Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710924683 PECOS PAC ID: 1759293954 Enrollment ID: O20031105000417 |
News Archive
Following a thorough safety review, including two meetings of the CDC's Advisory Committee on Immunization Practices, the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention have determined that the recommended pause regarding the use of the Johnson & Johnson (Janssen) COVID-19 Vaccine in the U.S. should be lifted and use of the vaccine should resume.
Johns Hopkins researchers say they have found a specific protein in nearly 100 percent of high-grade meningiomas - the most common form of brain tumor - suggesting a new target for therapies for a cancer that does not respond to current chemotherapy.
One-third of US workers now have high-deductible health plans, and those numbers are expected to grow in 2014 as implementation of the Affordable Care Act continues. There is concern that high-deductible health plans might cause enrollees of low socioeconomic status to forgo emergency care as a result of burdensome out-of-pocket costs.
Eli Lilly and Company has received its fourth U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.
The U.S. Government has proposed major changes in the rules covering research involving human subjects. Officials believe this would strengthen protections while reducing red tape that can impede studies. The experts cited vastly altered research climate as reasons for these recommendations. New features include genomics studies using patients' DNA samples, the use of the Internet and a growing reliance on studies that take place at many sites at once. The new rules cover topics like the informed consent that research participants must provide and the institutional review boards that oversee research at universities and hospitals.
› Verified 2 days ago
| Entity Name | Minnesota Eye Consultants, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508839879 PECOS PAC ID: 4284524539 Enrollment ID: O20040318001449 |
News Archive
Following a thorough safety review, including two meetings of the CDC's Advisory Committee on Immunization Practices, the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention have determined that the recommended pause regarding the use of the Johnson & Johnson (Janssen) COVID-19 Vaccine in the U.S. should be lifted and use of the vaccine should resume.
Johns Hopkins researchers say they have found a specific protein in nearly 100 percent of high-grade meningiomas - the most common form of brain tumor - suggesting a new target for therapies for a cancer that does not respond to current chemotherapy.
One-third of US workers now have high-deductible health plans, and those numbers are expected to grow in 2014 as implementation of the Affordable Care Act continues. There is concern that high-deductible health plans might cause enrollees of low socioeconomic status to forgo emergency care as a result of burdensome out-of-pocket costs.
Eli Lilly and Company has received its fourth U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.
The U.S. Government has proposed major changes in the rules covering research involving human subjects. Officials believe this would strengthen protections while reducing red tape that can impede studies. The experts cited vastly altered research climate as reasons for these recommendations. New features include genomics studies using patients' DNA samples, the use of the Internet and a growing reliance on studies that take place at many sites at once. The new rules cover topics like the informed consent that research participants must provide and the institutional review boards that oversee research at universities and hospitals.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Matthew Garrett Field, MD, PHD, MSPH 9801 Dupont Ave S Ste 425, Bloomington, MN 55431-3873 Ph: (952) 567-6125 | Matthew Garrett Field, MD, PHD, MSPH 9801 Dupont Ave S Ste 200, Bloomington, MN 55431-3200 Ph: (952) 888-5800 |
News Archive
Following a thorough safety review, including two meetings of the CDC's Advisory Committee on Immunization Practices, the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention have determined that the recommended pause regarding the use of the Johnson & Johnson (Janssen) COVID-19 Vaccine in the U.S. should be lifted and use of the vaccine should resume.
Johns Hopkins researchers say they have found a specific protein in nearly 100 percent of high-grade meningiomas - the most common form of brain tumor - suggesting a new target for therapies for a cancer that does not respond to current chemotherapy.
One-third of US workers now have high-deductible health plans, and those numbers are expected to grow in 2014 as implementation of the Affordable Care Act continues. There is concern that high-deductible health plans might cause enrollees of low socioeconomic status to forgo emergency care as a result of burdensome out-of-pocket costs.
Eli Lilly and Company has received its fourth U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.
The U.S. Government has proposed major changes in the rules covering research involving human subjects. Officials believe this would strengthen protections while reducing red tape that can impede studies. The experts cited vastly altered research climate as reasons for these recommendations. New features include genomics studies using patients' DNA samples, the use of the Internet and a growing reliance on studies that take place at many sites at once. The new rules cover topics like the informed consent that research participants must provide and the institutional review boards that oversee research at universities and hospitals.
› Verified 2 days ago
Honora E. Kennedy, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 9801 Dupont Ave S Ste 200, Bloomington, MN 55431 Phone: 952-888-5800 Fax: 952-567-6156 | |
Mehdi Roozbahani, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 9801 Dupont Ave S Ste 110, Bloomington, MN 55431 Phone: 612-355-6510 Fax: 612-713-9360 | |
Kaihan Fakhar, Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 8600 Nicollet Ave S, Bloomington, MN 55420 Phone: 952-541-2800 Fax: 952-886-7015 | |
Elizabeth A Davis, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 9801 Dupont Ave S, Suite 200, Bloomington, MN 55431 Phone: 952-888-5800 Fax: 952-884-2656 | |
Jefferson Berryman, Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 9801 Dupont Ave S Ste 200, Bloomington, MN 55431 Phone: 952-888-5800 Fax: 952-567-6156 | |
Jill Suzanne Melicher Larson, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 9801 Dupont Ave S, 200, Bloomington, MN 55431 Phone: 952-888-5800 | |
Thomas Lang, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 7920 Old Cedar Ave S, Bloomington, MN 55425 Phone: 952-428-1800 |